NEW YORK, Oct. 4, 2023 /PRNewswire/ -- The cell therapy market size is expected to grow by USD 31.04 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 57.06% during the forecast period, according to Technavio Research. The market has been segmented by type (autologous and allogenic), application (malignancies, musculoskeletal, cardiovascular, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). North America accounts for 40% of the growth of the global market during the forecast period. Factors such as the increased funding from governments and the growing number of regenerative medicine centers in the region, especially in countries such as the US, Canada, and Mexico. are increased funding from governments and the growing number of regenerative medicine centers in the region, especially in countries such as the US, Canada, and Mexico are significantly contributing to the growth of the global cell therapy market in North America. The US is one of the prominent markets in North America which contributes to the growth of the market in North America due to the increased funding offered by the government departments including NH and the Biomedical Advanced Research and Development Authority (BARDA) to small-scale industries and companies that are focusing on developing novel products. Hence, such factors are driving the market growth in the region during the forecast period.
This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read Free PDF Sample Report
Company Profile:
Astellas Pharma Inc., Athersys Inc., Avita Medical Inc., BioCardia Inc., BioSenic SA, Brainstorm Cell Therapeutics Inc., Bristol Myers Squibb Co., Capricor Therapeutics Inc., Castle Creek Biosciences Inc., CellSeed Inc., Cellular Biomedicine Group Inc., Celyad Oncology, SA Gilead Sciences Inc., Lineage Cell Therapeutics Inc., Lisata Therapeutics Inc., Mesoblast Ltd., Novartis AG Pharmicell Co. Ltd, Sanpower Group Co. Ltd., ThermoGenesis Holdings Inc.
Astellas Pharma Inc: The company offers cell therapy such as ASP7317 for the treatment of dry AMD.
- To gain access to more vendor profiles available with Technavio, buy the report!
Cell Therapy Market: Segmentation Analysis
The market share of the autologous segment will be significant during the forecast period. However, due to the several manufacturing complexities, there is only a moderate growth of this segment. In addition, the autologous segment of cell therapy has established its presence in both dermatology and musculoskeletal disorders segments. Therefore, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View Free PDF Sample Report
"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio
Cell Therapy Market: Driver & Trend:
- The proven effectiveness of CAR T-cell therapy.
There is a growing preference for VAR-T cell therapies as they tend to have higher efficacy than other therapies existing in the market for the treatment of cancer. The easy penetration of the cells into the cancer-causing cells in the patient due to the ability of f CAR to bind to the T-cell, especially when delivered through monoclonal antibodies is one of the significant advantages of this method. Furthermore, the CAR-T cells have proven to show an increasing safety profile in children with various types of blood cancers. Hence, such factors are driving the market growth during the forecast period.
- Increasing funding in cell-based research
- Limitations in traditional organ transplantations fueling demand for cell therapies
The rise in vaccine production is a primary trend in the market during the forecast period. Identify key trends, drivers, and challenges in the market. Download to gain access to this information.
What are the key data covered in this cell therapy market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the cell therapy market between 2022 and 2027.
- Precise estimation of the cell therapy market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the cell therapy market across North America, Europe, Asia, and ROW
- A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of cell therapy market vendors.
Related Reports:
The insomnia therapeutics market size is estimated to grow by USD 1,002.93 million at a CAGR of 5.49% between 2022 and 2027.
The gonorrhea therapeutics market size is estimated to grow by USD 506.68 million at a CAGR of 5.47% between 2022 and 2027.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Type
Market Segmentation by Application
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
![](https://rt.prnewswire.com/rt.gif?NewsItemId=CG28269&Transmission_Id=202310041400PR_NEWS_USPR_____CG28269&DateId=20231004)
Share this article